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ABSTRACT: The inhibitory effect of Juniperus phoenicea leaves 
extracts on Xanthine Oxidase activity was evaluated spectro-
photometrically at 290 nm. Extracts of Juniperus phoenicea showed a 
potent XO inhibitory activity. In order to isolate the active compounds, an 
in vitro bio-guided fractionation was undertaken by preparative 
chromatographic techniques. Fractions 2, 3 and 6 of ethyl acetate extract 
demonstrated substancial XO inhibitory activity (>80% inhibition) at 400 
μg/mL. The highest inhibitory effect was obtained for the fraction 3 
(87.8%). The major constituents amentoflavone (1) and catechin (2) 
isolated from the fraction 3 were identified by extensive spectroscopic 
studies including 1D and 2D NMR experiments. These two compounds 
have no inhibitory effect on xanthine oxidase, it is deduced that the XOI 
activity of the fraction 3, was due either to a minor bioactive compound 
or possible synergisms. However this study showed that the tested plant 
species is potential source of natural XO inhibitors that can be developed, 
upon further investigation, for treatment of gout and other XO-related 
disorders. 
INTRODUCTION: A common disease such as 
inflammation and related disorders are selected for 
our study and the primary target for treating these 
disorders includes the enzyme called xanthine 
oxidase (XO). The over-activity of this enzyme 
causes a disease called gout 
1
 and oxidative stress, 
which is characteristic for many vascular disease 
states 
2
 by generating superoxide anions. Gout is 
one of the most common metabolic disorders that 
affect humans.  
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It is characterized by marked hyperuricemia, 
leading to the deposition of urrate monohydrate 
crystals in the joint and kidney, leading to gouty 
arthritis and uric acid nephrolithiasis.  
The deposition of needle-shaped monosodium urate 
(UMS) crystals in the synovial fluid of the main 
joints produces acute, extremely painful arthritis 
with repeated attacks of gout 
3
. The treatment of 
gout involves increasing the excretion of uric acid 
or reducing its production. Inhibitors of xanthine 
oxidase (XOI) are very useful 
4
 because they 
reduces both vascular oxidative stress and 
circulating levels of uric acid and they have minor 
side effects compared to uricosuric and anti-
inflammatory agents. Allopurinol, widely used for 
the treatment of hyperuricemia and gout 
5
 have 
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many side effects such as hypersensitivity 
syndrome, Stevens-Johnson syndrome and renal 
toxicity 
6
. So, finding new XOI would be beneficial 
not only for treating gout but also for combating 
various other diseases 
7, 8
. 
Certain active constituents present in crude plant 
extracts like flavonoids and polyphenolic 
compounds have been reported to possess XOI
 9, 10, 
11
. These findings have opened the possibility of 
isolation of new natural compounds, which can be 
potent inhibitors of XO, and led to the growing 
interest in the investigation of medicinal plants. 
In this study, the medicinal plant Juniperus 
phoenicea was selected for its XOI activity by its 
ethnomedical use in the treatment of inflammatory 
and rheumatic diseases. 
Juniperus phoenicea called "Araar" in Arabic, is a 
tree or shrub up to 8 meters tall. This species 
extends from the Mediterranean region, occurring 
in southern Europe, western Asia and North Africa, 
also in eastern Portugal until in Turkey and Egypt, 
it extends from the Canary Islands to Saudi Arabia 
and Jordan, but is more common in the western part 
of the Mediterranean regions 
12, 13
. 
Previous phytochemical studies of Juniperus 
phoenicea revealed that diterepenes are the main 
secondary metabolites of the plant 
14, 15, 16
. 
Numerous biflavanoids including amentoflavone, 
robustaflavone, hinokiflavone, cupressuflavone and 
mono-O-methyl hinokiflavone were isolated from 
the leaf extract of Juniperus phoenicea 
17
. 
Flavonoids 
12
, phenylpropanoids 
18, 19, 20
, and 
furanones 
21, 22
 were also isolated from the plant. In 
the present studies in order to find new natural 
compounds, which can be potent inhibitors of XO 
we preceded to an Activity-guided phytochemical 
investigations of Juniperus phoenicea. 
MATERIALS AND METHODS:  
Chemicals: Analytical grade n-butanol (n-BuOH), 
ethyl acetate, chloroform and methanol (MeOH) 
employed for extraction isolation procedures were 
obtained from Merck, Methanol deuterated 
(CD3OD) and xanthine powder were purchased 
from Sigma-Aldrich Co. 
General Experimental Procedures: Column 
Chromatography was performed over Silica gel 
(63-200) µm, (Merck, Darmstadt, Germany). Thin-
layer chromatography (TLC) analysis was 
performed with precoated silica gel 60 F254 plates 
(Merck, Darmstadt, Germany), and the spray 
reagent cerium sulfate (saturated solution in dilute 
H2SO4) and UV (Shimadzu UV-1601, 254 and 366 
nm) were used for the spot visualization. 
Preparative TLC was performed with precoated 
silica gel 60 F254 aluminium sheets (20 × 20 cm, 
Merck, Darmstadt, Germany). The absorbance of 
XO-induced uric acid production from xanthine 
was measured at 290 nm, using the plate reader 
FluoSTAR OPTIMA (BMG LABTECH). A Bruker 
DRX-600 NMR spectrometer, operating at 599.19 
MHz for 1H and 150.858 MHz for 13C, using the 
WINXNMR software package, was used for NMR 
experiments in CD3OD. 
Plant Material: Aerial parts of Juniperus 
phoenicea were collected in from Tipaza area, 
located in north Algeria. A voucher specimen has 
been deposited in the Department of Chemistry, 
Algiers University. 
Extraction and Isolation: Air-dried and coarsely 
powdered (1000g) leaves were macerated at room 
temperature with MeOH–H2O (80:20, v/v) for 24 h, 
and the operation was repeated 3 times. After 
filtration, the filtrate was concentrated (methanol 
extract) and dissolved in H2O (400 ml). The 
resulting solution was extracted successively with 
chloroform, EtOAc and n-butanol. The organic 
phases were concentrated in vacuo at room 
temperature to obtain the following extracts: 
Chloroform (1.73g), EtOAc (4.42 g) and n-butanol 
(22.8 g). 
4 g of the EtOAc extract was fractionated over 
silica gel column using chloroform gradually 
enriched with ethyl acetate as eluent. Fractions 
were collected, and combined to 7 major fractions 
(F1-F7) based on TLC pattern. Fraction 3 was 
submitted to preparative TLC using as solvent a 
mixture of MeOH / H2O (8.5:1.5), to give two 
major constituents: amentoflavone (1) (5 mg) and 
catechin (2) (20 mg). 
Xanthine Oxidase Assay: The method is based on 
a modified protocol of Sigma 
23
. Spectro-
photometric determination of XO activity is based 
on measuring uric acid production (absorbance) 
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from xanthine or hypoxanthine substrate at 290 nm 
for 3 min in a 96-well plate, using the plate reader 
FluoSTAR OPTIMA. The XO inhibitory effect was 
determined via the decreased production of uric 
acid. Reagents were 50 mM potassium phosphate 
buffer, pH 7.5 with 1M KOH, 0.15 mM xanthine 
solution (pH 7.5), and XO solution (0.2 units/mL). 
XO, isolated from bovine milk (lyophilized 
powder). The different extracts (12 mg/mL) were 
prepared in dimethyl sulfoxide (DMSO). For 
enzyme activity control, the final reaction mixture 
was made with 100 μL of xanthine, 150 μL 
ofbuffer and 50 μL of XO in a 300 μL well. The 
reaction mixture for inhibition comprised 100 μL of 
xanthine, 140 μL of buffer, 10 μL of sample and 50 
μL of XO. Allopurinol served as positive control. 
All the experiments were conducted in triplicate. 
The reaction was initiated by the automatic 
addition of 0.050 mL of XO solution to a final 
concentration of 0.006 units/mL. 
RESULTS AND DISCUSSION: The XOI activity 
of extracts was calculated as % xanthine oxidase 
inhibition activity = 1- (XOIs /XOIo) x 100 %, 
where XOIs is enzyme activity with test sample 
and XOIo is enzyme activity without sample. The 
XOI activity of extracts and fractions were 
summarized in Table 1. 
TABLE 1: PERCENTAGE OF DPPH RADICAL 
SCAVENGING ACTIVITY AND XANTHINE OXIDASE 
INHIBITORY ACTIVITY 
Samples (400 µg/mL) XOI Activity (% ± SD) 
Methanol extract 
n-butanol extract 
Ethyl acetate extract 
F1 
F2 
F3 
F4 
F5 
F6 
F7 
42.12 ± 3.2 
70.7 ±  8.4 
70.2  ± 4.7 
58.4 ±   8.2 
81.5  ±  2.3 
87.8 ±  4.5 
75.1  ± 1.3 
73.5  ± 1.6 
85.6  ±  4.2 
70.7 ±  6.5 
At 400 μg/mL, all of the investigated extracts 
displayed significant XO inhibitory activities. 
Fractions of ethyl acetate extract demonstrated 
substantial XO inhibitory activity (≥50% 
inhibition), among them F2, F3 and F6 exhibited 
a>80% inhibitory effect. The most potent inhibitory 
effect was obtained for the fraction 3 Table 1, 
hence we chose it to continue the separation of our 
extract in order to find the compounds responsible 
for this inhibitory activity (XOI). 
The major constituents of this fraction were 
identified as a bioflavonoid amentoflavone (1) and 
a flavanol catechin (2) on the basis of spectral 
evidences and comparison of spectral data with 
literature value 
17, 24
. The presence of compounds 1 
and 2 in Juniperus phoenicea was already 
mentioned 
17
. 
Phenolic and flavonoid compounds are reported to 
possess XOI activities. Flavonoids that selected as 
potential XO inhibitor should consists either 
hydroxyl group at C-5 and C-7, or double bond 
between C-2 and C-3 
25, 26
. According to Nagao et 
al, lower inhibitory activities among some 
flavonoids are due to substitution of hydroxyl 
groups at C-3 and C-7 by glycoside or methyl 
group 
26
 and some flavonoids that showed minimal 
or no XOI are such as catechin, non-planar 
flavones and isoflavones 
26
. In these studies, 
compounds 1 and 2 do not possess XOI activity, we 
can deduce that the activity of fraction 3 was due 
either to a minor bioactive constituent or possible 
synergisms between polyphenols present in the 
fraction. 
CONCLUSION: These studies revealed the 
potential of Juniperus phoenicea leaves to inhibit 
xanthine oxidase wich therefore may have a 
positive impact on the prevention of disease caused 
by increased activity of XO. It is suggested that 
further purification such as silica gel vacuum 
chromatography and HPLC of fractions 2, 3, and 6 
shall be carried out to identify a potential chemical 
entity for clinical use in the prevention and 
treatment of gout and related inflammatory 
disorders. Furthermore, in vivo XOI activity assay 
can be done to further prove the antigout property 
of this medicinal plant. 
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